<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Cambridge Centre for Brain Repair</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7A228825-29AE-4056-98F4-B70F9309B430"><gtr:id>7A228825-29AE-4056-98F4-B70F9309B430</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>Fawcett</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6E21A7D6-BE0F-45B5-9AAD-25FE1CE982B1"><gtr:id>6E21A7D6-BE0F-45B5-9AAD-25FE1CE982B1</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:surname>ffrench-Constant</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701518"><gtr:id>10A3AFE2-1DE6-47A8-8CE2-E5543C6120B0</gtr:id><gtr:title>Integrin engineering to promote axon regeneration and Schwann cell migration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701518</gtr:grantReference><gtr:abstractText>After damage to the spinal cord or brain many nerve fibres are cut. In spinal cord injury this means that motor commands from the brain cannot reach muscles, and sensory information from the skin cannot reach the brain. In order to produce a cure the nerve fibres have to be made to regenerate from the injury point back into the spinal cord and up towards the brain. At present nerve fibre regeneration after spinal cord damage does not succeed, due to many factors such as the scar tissue at the injury site that blocks nerve fibre growth. In the scar tissue there is a molecule called tenascin which nerve fibres could use to grow on, but they lack the receptor molecules to interact with tenascin. The project will put the necessary type of receptor molecules (integrins) on the cut nerve fibres, and will make further modifications to the integrins to prevent them being turned off by inhibitory factors in the scar tissue. A second part of the project is to take a cell type called Schwann cells, which can promote nerve fibre growth, and implant them into spinal cord injuries as a bridge over which the regenerating nerve fibres can grow. In order to make it possible for these cells to integrate into the spinal cord they will also have modifications to their surface integrins.</gtr:abstractText><gtr:technicalSummary>The aim of the grant is to develop a new set of tools for structural repair of the damaged spinal cord, base on the manipulation of integrins. By engineering integrin expression, trafficking, activation and signalling we aim to promote axon regeneration, and to increase the ability of Schwann cells to migrate and integrate into the CNS environment. Tenascin-C is upregulated in the damage spinal cord, so we have identified an integran that interacts with it. Proof of principle that expression of a tenascin-binding integrin can promote axon regeneration has already been obtained. However we believe that in the adult CNS inhibitory mechanisms may interfere with integrin activation, trafficking and signalling. We have interventions to counteract these potential influences, and will apply them one by one until we have a successful integrin strategy for promoting CNS repair. This builds on previous work in the applicant?s laboratories on axon regeneration, Schwann cell migration and integrins. It also builds on work by our collaborators on integrin trafficking and activation. The tools for the work are mostly already made, but they have not previously been applied to axon regeneration or Schwann cell migration. The project also builds on spinal cord injury models and methods for behavioural assessment developed in the Fawcett laboratory. Repair of CNS damage will require the integration of several treatments; integrin engineering will probably be an important part of these treatments.</gtr:technicalSummary><gtr:fund><gtr:end>2012-02-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>824759</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Max Planck Society</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Max Planck Institute of Biochemistry</gtr:department><gtr:description>Fassler</gtr:description><gtr:id>FD5C3F84-74DD-4CE6-B9BC-533CE4DE939E</gtr:id><gtr:impact>Paper submitted to J. Neurosci.
Kindlin-1 enhances axon growth on inhibitory CSPGs and promotes sensory axon regeneration</gtr:impact><gtr:outcomeId>qLCwSNiE6Rj-1</gtr:outcomeId><gtr:partnerContribution>tools and knowledge for integrin activators</gtr:partnerContribution><gtr:piContribution>We started a collaboration with Reinhard Fassler on integrin activation using kindlins and talin. Fassler provided the tools, the research has been done in Cambridge</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Schools</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>B8A13972-F93B-4EFD-80EB-5877C2D8FCF1</gtr:id><gtr:impact>Two talks to local secondary schools.
approx 60 attendees

More applicants to Cambridge</gtr:impact><gtr:outcomeId>WXzAC39i4ty</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>physios</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>B493A040-B81A-4050-8FA0-ECC6A42EE856</gtr:id><gtr:impact>Annual physio meeting

Updates on prospects for spinal injury patients</gtr:impact><gtr:outcomeId>18EF23CBF5D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>outreach programme</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>86C6470D-16D2-4A3D-B0EC-77F8E180FAA8</gtr:id><gtr:impact>Approx 100 pupils from mostly foreign schools

Interest in university in UK</gtr:impact><gtr:outcomeId>UM6Fhn2uGe8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>spinal injury lawyers</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>C365B39F-FD4F-48E7-A019-450672832B3E</gtr:id><gtr:impact>updating spinal injury lawyers and patients

changing damages requests</gtr:impact><gtr:outcomeId>94BCC47C9CB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>spinal injury physicians</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>35672F1F-BFC1-46EC-AEAD-F6828DB3DAEA</gtr:id><gtr:impact>Approx 300 spinal injury professionals. 
Washington ASIA meeting

Interest in future developments</gtr:impact><gtr:outcomeId>FiynFUTW8yB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>FF6BFABD-3D91-49E3-945C-3E17A1F76943</gtr:id><gtr:outcomeId>YvT8D9jN8Qo0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Patent applied for; stimulation of axon regeneration by alpha9 integrin</gtr:description><gtr:grantRef>G0701518</gtr:grantRef><gtr:id>61382C16-AAB7-47F3-A188-A86B6E49A403</gtr:id><gtr:impact>no</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>893ADF390FA</gtr:outcomeId><gtr:patentId>WO2007083133</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>alpha9 integrin in axon regeneration</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>advising Novartis and three other pharma companies</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>EFD90AFB-2C6C-418D-942F-EC3FBCD45061</gtr:id><gtr:impact>Setting up clinical trials in spinal cord injury</gtr:impact><gtr:outcomeId>TwNyyErv6jg</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BIRAX</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>4387265D-60DF-4629-B88C-16ED38F95592</gtr:id><gtr:outcomeId>58c7f5788cbae0.92818045</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bristol review</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>16CB7793-71FC-4E78-924E-345D26403668</gtr:id><gtr:outcomeId>58c7f5cf92b616.90546810</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>physios</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>E09D42A0-5E98-41E2-9C77-43DF141DF4A6</gtr:id><gtr:impact>changing treatment of spinal injury patients</gtr:impact><gtr:outcomeId>C613C6A1FD9</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Viral vectors for expression of integrins, chondroitinase</gtr:description><gtr:id>CEBF4161-FFCC-46CD-9D7D-85BF5F3AD398</gtr:id><gtr:impact>Experiments on viral expression of chondroitinase</gtr:impact><gtr:outcomeId>LuPqwU4dcW8</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>viral vectors</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F601D899-B90D-413F-93AA-8092AC338F3B</gtr:id><gtr:title>Selective rab11 transport and the intrinsic regenerative ability of CNS axons.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/836576d0364ce8b0fc9957c35becfa79"><gtr:id>836576d0364ce8b0fc9957c35becfa79</gtr:id><gtr:otherNames>Koseki H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>5aa69f43346fd7.46773120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>708B9791-B00D-4532-8672-1791BA285B33</gtr:id><gtr:title>Up-regulation of oligodendrocyte precursor cell alphaV integrin and its extracellular ligands during central nervous system remyelination.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcd2f88320855c9e0c59074101de3d8e"><gtr:id>dcd2f88320855c9e0c59074101de3d8e</gtr:id><gtr:otherNames>Zhao C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0360-4012</gtr:issn><gtr:outcomeId>8B5203F9A82</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>758ED88F-DB2A-40E4-BB33-D3D154FAAC37</gtr:id><gtr:title>Astrocyte-produced ephrins inhibit schwann cell migration via VAV2 signaling.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4417d5eae76735abd8c72172da3a9523"><gtr:id>4417d5eae76735abd8c72172da3a9523</gtr:id><gtr:otherNames>Afshari FT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>TPCwtuRcLbX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8FB7BAA-96DD-41EA-9C14-5757266937A5</gtr:id><gtr:title>The kinesin-2 family member KIF3C regulates microtubule dynamics and is required for axon growth and regeneration.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd8a4927287b3fb89638c0b06a1d0c04"><gtr:id>fd8a4927287b3fb89638c0b06a1d0c04</gtr:id><gtr:otherNames>Gumy LF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>pm_16200_20_23843507</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A832110-9CB1-41D4-BA91-F713F399BA2A</gtr:id><gtr:title>Chondroitinase ABC treatment opens a window of opportunity for task-specific rehabilitation.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d3f066faae75e37a2caa4255313f4bc"><gtr:id>3d3f066faae75e37a2caa4255313f4bc</gtr:id><gtr:otherNames>Garc?a-Al?as G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn><gtr:outcomeId>pm_16200_10_19668200</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC810375-BC0B-4D24-B1FA-A8BF52543BCB</gtr:id><gtr:title>Integrin activation or alpha 9 expression allows retinal pigmented epithelial cell adhesion on Bruch's membrane in wet age-related macular degeneration.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4417d5eae76735abd8c72172da3a9523"><gtr:id>4417d5eae76735abd8c72172da3a9523</gtr:id><gtr:otherNames>Afshari FT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>B6aCbJRiZtN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3600DF59-20CC-4755-9829-2D2FFA58B3C3</gtr:id><gtr:title>Alpha9 integrin promotes neurite outgrowth on tenascin-C and enhances sensory axon regeneration.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76db304c22229075b07a33e8932b79de"><gtr:id>76db304c22229075b07a33e8932b79de</gtr:id><gtr:otherNames>Andrews MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>837A92CF833</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>958C2A0D-E7B1-417C-9008-2FE41E0D3FA2</gtr:id><gtr:title>Rab11 and its effector Rab coupling protein contribute to the trafficking of beta 1 integrins during axon growth in adult dorsal root ganglion neurons and PC12 cells.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ebd82a1e1822f8b5d4aff4d5af2d422"><gtr:id>8ebd82a1e1822f8b5d4aff4d5af2d422</gtr:id><gtr:otherNames>Eva R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>PZ6ch2uVuHm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F27A35B7-2F77-4998-9C49-D0A787C84C50</gtr:id><gtr:title>Schwann cell migration is integrin-dependent and inhibited by astrocyte-produced aggrecan.</gtr:title><gtr:parentPublicationTitle>Glia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4417d5eae76735abd8c72172da3a9523"><gtr:id>4417d5eae76735abd8c72172da3a9523</gtr:id><gtr:otherNames>Afshari FT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0894-1491</gtr:issn><gtr:outcomeId>Rj7gzemE1Mv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8700A869-8928-442D-8C28-122E3B4C1D34</gtr:id><gtr:title>Integrin activation promotes axon growth on inhibitory chondroitin sulfate proteoglycans by enhancing integrin signaling.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/106c063dfa5fa46bd35ebd7828c2d3a9"><gtr:id>106c063dfa5fa46bd35ebd7828c2d3a9</gtr:id><gtr:otherNames>Tan CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>JpEmex4JTbL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB7C91ED-910A-4447-93E0-4599E89ED6EF</gtr:id><gtr:title>Disc1 variation leads to specific alterations in adult neurogenesis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdff80894e051af5280a903c3c0e0922"><gtr:id>fdff80894e051af5280a903c3c0e0922</gtr:id><gtr:otherNames>Chandran JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5675dc0fe67e0</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701518</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>